{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:33:42Z","timestamp":1792071222468,"version":"4.4.0"},"reference-count":27,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,5]]},"DOI":"10.2967\/jnumed.124.268902","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:15:27Z","timestamp":1740672927000},"page":"707-712","source":"Crossref","is-referenced-by-count":25,"title":["<sup>177<\/sup>Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial"],"prefix":"10.2967","volume":"66","author":[{"given":"Andreas","family":"Hallqvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elva","family":"Brynjarsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Krantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Sj\u00f6gren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2025050105251677000_66.5.707.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2025050105251677000_66.5.707.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"2025050105251677000_66.5.707.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-3945-z"},{"key":"2025050105251677000_66.5.707.4","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","article-title":"Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients","volume":"49","author":"Sundlov","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251677000_66.5.707.5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251677000_66.5.707.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1631-x"},{"key":"2025050105251677000_66.5.707.7","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2012.1276"},{"key":"2025050105251677000_66.5.707.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0688-7"},{"key":"2025050105251677000_66.5.707.9","doi-asserted-by":"crossref","first-page":"S4608","DOI":"10.1200\/JCO.2022.40.16_suppl.4122","article-title":"Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)\u2014final result [abstract]","volume":"40","author":"Pavlakis","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025050105251677000_66.5.707.10","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2015.1876"},{"key":"2025050105251677000_66.5.707.11","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/biom14101269","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for cancer therapy: advances, challenges, and future directions","volume":"14","author":"Bondar","year":"2024","journal-title":"Biomolecules."},{"key":"2025050105251677000_66.5.707.12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11912-017-0567-8","article-title":"Radionuclide therapy for neuroendocrine tumors","volume":"19","author":"Cives","year":"2017","journal-title":"Curr Oncol Rep."},{"key":"2025050105251677000_66.5.707.13","doi-asserted-by":"publisher","DOI":"10.7150\/thno.15311"},{"key":"2025050105251677000_66.5.707.14","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3390\/biomedicines9111570","article-title":"Optimizing the schedule of PARP inhibitors in combination with 177Lu-DOTATATE: a dosimetry rationale","volume":"9","author":"Hallqvist","year":"2021","journal-title":"Biomedicines."},{"key":"2025050105251677000_66.5.707.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2766"},{"key":"2025050105251677000_66.5.707.16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2656-8"},{"key":"2025050105251677000_66.5.707.17","doi-asserted-by":"crossref","first-page":"10196","DOI":"10.1038\/s41598-020-67199-9","article-title":"Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP","volume":"10","author":"Cullinane","year":"2020","journal-title":"Sci Rep."},{"key":"2025050105251677000_66.5.707.18","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25266"},{"key":"2025050105251677000_66.5.707.19","first-page":"C23","article-title":"Phase 1\/2 study of Lu-177-DOTATATE in combination with olaparib in metastatic or inoperable GI neuroendocrine tumors: first results [abstract]","volume":"98","author":"Lin","year":"2023","journal-title":"Endocrine Abstracts."},{"key":"2025050105251677000_66.5.707.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.258889"},{"key":"2025050105251677000_66.5.707.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1026"},{"key":"2025050105251677000_66.5.707.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263230"},{"key":"2025050105251677000_66.5.707.23","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2967\/jnumed.120.258376","article-title":"First-in-humans application of 161Tb: a feasibility study using 161Tb-DOTATOC","volume":"62","author":"Baum","year":"2021","journal-title":"J Nucl Med."},{"key":"2025050105251677000_66.5.707.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01663-7"},{"key":"2025050105251677000_66.5.707.25","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1007\/s00259-024-06827-2","article-title":"Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting","volume":"51","author":"Busslinger","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251677000_66.5.707.26","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s00259-024-06641-w","article-title":"First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum","volume":"51","author":"Fricke","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251677000_66.5.707.27","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T12:25:26Z","timestamp":1746102326000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.2967\/jnumed.124.268902"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268902","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}